9999999997-16-025635.txt : 20160908 9999999997-16-025635.hdr.sgml : 20160908 20160908124327 ACCESSION NUMBER: 9999999997-16-025635 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20160908 DATE AS OF CHANGE: 20160908 20160908 20160908 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PDL BIOPHARMA, INC. CENTRAL INDEX KEY: 0000882104 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943023969 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1934 Act SEC FILE NUMBER: 000-19756 FILM NUMBER: 161875448 BUSINESS ADDRESS: STREET 1: 932 SOUTHWOOD BLVD CITY: INCLINE VILLAGE STATE: NV ZIP: 89451 BUSINESS PHONE: 775-832-8500 MAIL ADDRESS: STREET 1: 932 SOUTHWOOD BLVD CITY: INCLINE VILLAGE STATE: NV ZIP: 89451 FORMER COMPANY: FORMER CONFORMED NAME: PROTEIN DESIGN LABS INC/DE DATE OF NAME CHANGE: 19930328 CT ORDER 1 filename1.pdf begin 644 filename1.pdf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